A Systematic, Patient-Centered Approach to Managing Patients with CLL

Curriculum:
A Systematic, Patient-Centered Approach to Managing Patients with CLL
Credits:
AANP Contract Hours 1.2 ANCC Contract Hours CA-BRN 1.25 AMA PRA Category 1 Credit(s)™
Launch Date:
31-Aug-17
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Oncology clinicians including physicians, nurses, nurse practitioners, and PAs

Relevant Terms:

Chronic lymphocytic leukemia

Ian W. Flinn, MD, PhD

Ian W. Flinn, MD, PhD
Director of Lymphoma/CLL Program
Sarah Cannon Center for Blood Cancer
Nashville, TN

Ian W. Flinn, MD, PhD, is director of the Blood Cancer Research Program at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr Flinn also serves as director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology and TriStar Centennial Medical Center.
 
Dr Flinn received his bachelor's degree in economics from Georgetown University in Washington, D.C., and graduated from Johns Hopkins University School of Medicine in Baltimore, Maryland. He then completed his internship and residency at the University of Michigan Medical Center in Ann Arbor, Michigan. He earned a fellowship in oncology and hematology, as well as a PhD in clinical investigations from Johns Hopkins University School of Medicine. Before joining the Sarah Cannon Research Institute, Dr Flinn was an associate professor of Oncology at Johns Hopkins, where he also served as director of the Lymphoma Program and assistant director for Clinical Research at the Sidney Kimmel Comprehensive Cancer Center.
 
Dr Flinn's clinical practice is restricted to patients with hematologic malignancies, particularly those with lymphoma and chronic lymphocytic leukemia. His research is focused on the development of new therapies for patients with these disorders. These studies range from first in human to phase 3 trials.
1. Utilize disease characteristics such as cytogenetic and molecular features, and patient factors, to make appropriate treatment selection for patients with CLL
2. Incorporate novel and emerging therapies into the clinical management of patients with CLL taking into account safety and efficacy and clinical trial utilization data
3. Effectively manage adverse events associated with approved and emerging treatments for CLL
4. Engage patients with advanced CLL in their healthcare by implementing effective shared decision-making strategies 

PHYSICIAN CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.  This educational activity for 1.2 contact hours is provided by the Postgraduate Institute for Medicine. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
 
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Ian Flinn, MD, PhD, has affiliations with Celgene, Genentech, Gilead, Janssen, and Pharmacyclines (Contracted Research). 
RMEI Medical Education, LLC
  • Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
  • Kate Mann, PharmD, has affiliations with Otsuka (Spouse: Consulting Fees). 
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Katie Barry has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 1.25 hours
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

COMMERCIAL SUPPORT
This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by independent educational grants from AbbVie and Genentech.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1.25 AMA PRA Category 1 Credit(s)™, 1.2 ANCC contact hours, and 0.5 APRN contact hours. A statement of credit will be available to print from your user history page. Users must:
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.